CAMBRIDGE, MA, November 15, 2017 – The CEO of Aurora BioPharma, Robert Brooks, will attend the Redefining Early Stage Investments (RESI) Conference on November 15, 2017 at the New York Marriott Marquis.
Life Science Nation (LSN) has launched New York City's first Redefining Early Stage Investments (RESI) Conference. RESI NYC will bring together more than 400 fundraising CEOs and nearly 400 early stage investors from around the globe, providing the opportunity for dialogue and relationship building, with the goal of eventual capital allocations. The RESI conference focuses on the diverse breadth of early stage investors that LSN tracks, including Family Offices, Venture Philanthropy Funds, Corporate Venture, VCs, Angel Groups and Capital Funds. The recent RESI Conference in San Francisco attracted nearly 1000 participants and a full partnering floor. Fundraising executives can participate in scheduled meetings through RESI Partnering, as well as ad-hoc events with diverse life science investors who fit their company's technology sector, indication and stage of development.
Aurora is leading in the development of Chimeric Antigen Receptor (CAR) T therapy in solid tumors, with a diversified mid-stage clinical pipeline. Aurora's CAR T drug AU105 completed Phase I/IIa clinical trial in 16 Glioblastoma patients showing safety, tumor killing efficacy, double the median historic overall survival, with 3 patients alive after 5 years. Aurora's CAR T drug AU101 completed a Phase IIa trial in 6 Sarcoma patients, showing safety, tumor-killing and a Complete Response ---cancer free after 5 years. Aurora is planning a pivotal trial of its CAR T Cell therapy in Glioblastoma and Osteosarcoma.
Internet: www.aurora-biopharma.com
This press release and any statements of representatives and partners of Aurora BioPharma, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors, many of which are beyond the Company's control. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Candace Cobos
Aurora BioPharma, Inc.
Tel: (617) 674-7718
Fax: (617) 674-7701
candace.cobos@aurora-biopharma.com
SOURCE Aurora BioPharma, Inc.